Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
With
Chugai Pharmaceutical
Age
20–74
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically documented breast cancer.
Patients with hormone receptor (ER and/or PgR) status of positive or unknown
Patients who have been amenorrheic for the preceding 12 months or more.
Patients who are 20 years or older and younger than 75 years.
Patients with a history of postoperative adjuvant therapy or a history of endocrine therapy with tamoxifen for the treatment of progression or recurrence of the lesion. The endocrine therapy, however, should not exceed one regimen.
Patients with progressing lesions.
Patients with sufficient organ function to evaluate the safety
Patients whose performance status (PS) is classified in 0～2.
Patients who have no residual effects from previous treatments
You may not be if
Patients with other concurrent or previous malignant disease (excluding uterine carcinoma in-situ).
Patients with hypercalcemia and uncontrollable cardiac disease (including a history of serious cardiac disease)
Patients who have previously received aromatase inhibitor.
Patients who have lymphangitis-type lung metastasis or symptomatic brain metastasis.
Clareo Health | Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
